Insmed (INSM) Shares Climb +23.5% Over 30 Days Following Strong Earnings and Approvals
Key Takeaways
- Insmed (INSM) shares rose roughly 23.5% over the past 30 days, from about $98.60 to $121.82, driven primarily by a strong second-quarter 2026 earnings report and raised guidance.
- The stock surged approximately 34% in a single session on August 6, 2026, after the company reported sharply narrower losses and nearly quadrupled product revenue.
- Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib) in late August, extending the product's reach to a third major market.
- Over the trailing three months, INSM advanced about 15%, rebounding from a 52-week low of $90.39 touched in early June.
- Management raised its 2026 BRINSUPRI revenue outlook to $1.25 billion to $1.40 billion and lifted its combined peak-sales estimate for its three lead programs to more than $14 billion.
Insmed (INSM) Company Background and Market Position
Insmed Incorporated is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, focused on developing and commercializing therapies for serious and rare diseases. Its portfolio spans three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The company currently markets two approved products — ARIKAYCE (amikacin liposome inhalation suspension), an inhaled treatment for Mycobacterium avium complex (MAC) lung disease, and BRINSUPRI (brensocatib), an oral, once-daily therapy for non-cystic fibrosis bronchiectasis (NCFB), a chronic and progressive inflammatory lung disease. Investors follow the stock closely because of the rapid commercial launch of BRINSUPRI, the label-expansion opportunity for ARIKAYCE, and a late-stage pipeline led by TPIP, an investigational inhaled prostacyclin for multiple pulmonary hypertension indications. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
INSM Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, INSM climbed approximately 23.5%, advancing from a close of $98.60 on July 31, 2026, to $121.82 by August 31, 2026. The move was concentrated in early August, when the stock jumped from $99.02 to $132.55 in a single session following second-quarter results. Shares subsequently consolidated in the $120 to $135 range before settling near $121.82.
The trailing three-month picture tells a broader story. After opening June near $106, the stock slid to a 52-week low of $90.39 on June 10 amid index-related selling and post-earnings pressure, then recovered through July. The August earnings-driven surge pushed the quarter-to-date gain to roughly 15%, though the path was marked by significant volatility. The stock remains well below its 52-week high of $212.75, which was reached in December 2025.
What Drove the Recent Move in INSM Shares
The dominant catalyst was the company's second-quarter 2026 financial report, released August 6. Insmed reported a net loss of $13.24 million, or $0.06 per share, a sharp narrowing from a loss of $321.69 million, or $1.70 per share, a year earlier. Net product revenue nearly quadrupled to $425.49 million, led by $309.2 million in BRINSUPRI sales, which rose 49% sequentially, while ARIKAYCE revenue increased 8% year over year to $116.3 million.
Management raised its full-year 2026 BRINSUPRI revenue guidance to a range of $1.25 billion to $1.40 billion, up from a prior target of at least $1.0 billion, and reaffirmed ARIKAYCE guidance of $450 million to $470 million. The company also increased its combined peak-sales estimate for its three lead programs to more than $14 billion, citing greater than $7 billion for BRINSUPRI and greater than $6 billion for TPIP. A second catalyst arrived on August 24, when Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI for NCFB, making it the first and only approved therapy for the condition in Japan and extending availability to a third major market alongside the United States and Europe. Analyst reactions following the earnings report were generally constructive, with several firms reaffirming positive ratings and raising price targets. From what I see, the data lines up with a solid commercial trajectory.
Performance Drivers Across the Full Quarter for INSM
The quarter was defined by a sharp drawdown followed by a powerful recovery. In early June, INSM fell to a 52-week low of $90.39, pressured in part by the company's removal from the NASDAQ-100 Index and certain Russell indices, which triggered passive fund selling, as well as lingering investor caution following earlier quarterly results. The stock stabilized and began rebuilding through July as sentiment around the BRINSUPRI launch improved. The August 6 earnings report then served as a turning point, with better-than-expected BRINSUPRI revenue, a substantially narrower loss, and raised guidance restoring confidence in the commercial trajectory. The Japanese approval in late August reinforced the global expansion narrative, helping the stock hold most of its gains into the end of the month.
Key Outlook Drivers Investors Should Monitor for INSM
Several factors will shape the outlook for INSM going forward. Investors will monitor the continued ramp of BRINSUPRI in the United States and Europe and the early launch in Japan following approval. The company's supplemental New Drug Application for ARIKAYCE in newly diagnosed MAC lung disease, submitted in July 2026 based on positive Phase 3b ENCORE data, represents a potential label-expansion catalyst. Pipeline progress is also central, with TPIP Phase 3 studies in pulmonary hypertension enrolling and additional Phase 3 initiations planned. Key financial considerations include management's expectation of reaching cash flow positivity in 2027 without additional capital raises, supported by roughly $1.2 billion in cash and marketable securities as of June 30, 2026. Risks include competitive dynamics in respiratory markets, payer and reimbursement decisions, and execution risk tied to a heavy reliance on BRINSUPRI for near-term growth. I’m watching this closely as the launch metrics unfold.
Using Tickeron AI Trading Bots for Market Insights
In my research, I often turn to Tickeron’s AI Trading Bots to explore systematic strategies across different timeframes and risk levels. These tools help compare approaches that align with individual objectives, offering a practical way to supplement fundamental analysis without replacing it. The platform features hundreds of bots, with top performers highlighted for easier review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
INSM sees MACD Histogram crosses below signal line
INSM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 24, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 44 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INSM moved out of overbought territory on August 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 26 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 59 cases where INSM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INSM as a result. In 67 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
Bullish Trend Analysis
Following a +3.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 214 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (34.602) is normal, around the industry mean (25.951). P/E Ratio (0.000) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (436.793).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement